Opzelura^TM (Ruxolitinib) Cream 1.5

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition.
• Current treatments include topical corticosteroids, calcineurin inhibitors, and PDE4 inhibitors.
• Some patients require alternative or adjunctive therapies for controlled AD.

Purpose of the Study:

• To introduce Ruxolitinib cream 1.5% (Opzelura™) as a treatment option for mild to moderate atopic dermatitis.
• To describe the mechanism of action of Ruxolitinib in targeting AD inflammation.
• To outline the approved usage guidelines for Ruxolitinib cream in eligible patients.

Main Methods:

• Ruxolitinib cream 1.5% selectively inhibits Janus kinase (JAK) 1 and JAK2.
• This inhibition blocks signaling pathways involving key cytokines like IL-4, IL-13, IL-31, and TSLP.
• Topical application is recommended twice daily to affected lesions up to 20% body surface area.

Main Results:

• Ruxolitinib cream targets the JAK-STAT pathway to reduce cutaneous inflammation.
• It interrupts cytokine signaling crucial for AD pathogenesis, including itching and inflammation.
• The cream is indicated for short-term, non-continuous treatment in non-immunocompromised patients aged 12+.

Conclusions:

• Ruxolitinib cream 1.5% provides a targeted topical therapy for atopic dermatitis.
• Its mechanism of action addresses key inflammatory mediators in AD.
• It offers an alternative for patients whose AD is not adequately controlled by other topical treatments.